Non-Depolarizing Muscle Relaxants (3) Flashcards

1
Q

How do we decide which NDMB to use?

A

influenced by differences in
* Onset
* Duration of action
* Rate of recovery
* Metabolism

usually base choice on DOA and comorbidities of the pt

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is the MOA of NDMB?

A
  • Act at pre-junctional sites to block Ach release
  • Competitive inhibitors for alpha subunits on nACHRs
  • Bind and do not cause conformation change
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What are characteristics of NDMB associated with nerve stimulation and reversals?

A
  • Decreased twitch response to a single stimulus
  • Unsustained response (fade) to continuous stimulus
  • TOF ratio < 0.7
  • Post-tetanic potentiation
  • Potentiation of other non-depolarizing drugs
  • Antagonism by anticholinesterase drugs
  • No fasciculations during onset
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What does the “fade” with NDMB suggest?

A

Some fibers are contracting while some are blocked

  • some are more susceptible to NMBD
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What are adverse side effects to NDMB?

A
  • Cardiovascular effects
  • Critical illness myopathy
  • Altered responses
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What causes cardiovascular effects associated with NDMBs?

A
  • release of histamine
  • effects at cardiac muscarinic receptors
  • effects on nAchRs at autonomic ganglia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What are the cardiovascular effects associated with NDMBs?

A
  • Varies between patient d/t underlying disease and preop meds
  • rarely clinically significant
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What is a autonomic margin of safety?

A

Difference between dose that produces blockade (ED95) and dose that creates circulatory effects

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What is the autonomic margin of safety for pancuronium?

A

Same as the normal dose

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What is critical illness myopathy?

A

Skeletal muscle weakness

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

When can critical illness myopathy occur?

A
  • Weeks to months after NMBD discontinued
  • patient with multiorgan fx vent >6 days
  • usually from aminosteroid blocker
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What potentially enhances risk of critical illness myopathy?

A

Large dose glucocorticoids prior to NMBD

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is the MOA of critical illness myopathy?

A

unknown

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Why do you want to stick with the same NDMB once you pick one?

A

If you switch to another one to redose then they compound on each other and it will be hard to get pt reversed

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

How do volatiles affect NMBs?

A

Dose dependent enhancement of muscle relaxation with onset as early as 30 minutes

Des>Sevo>Iso

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What are some drugs that enhance or antagonize blockade and what is the MOA?

A

Diuretics, Corticosteroids, Metoclopromide, LA

  • increase Ach release
  • depression of cholinesterase activity
  • depression of nerve conduction
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Magnesium ________ blockade of NMBs

A

enhances

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What is MOA of magnesium increasing non depolarizing NMBs?

A
  • decreases prejunctional release of Ach
  • decreases sensitivity to postjunctional membranes
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

What does giving ephedrine prior to non-depolarizing NMBs cause?

A

Decrease onset time from increase in CO and skeletal muscle flow

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

How does esmolol prior to induction affect non-depolarizing NMBs?

A

delays onset of the paralytic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Why is it important to prevent hypothermia in patients?

A

Even mild hypothermia double duration of vec and pancuronium through slowing of hepatic enzyme activity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Which NDMB are somewhat temperature dependent on metabolism?

A

Atracurium and Cisatracurium
- hoffman elimination and ester hydrolysis (need to have pretty close to normal body temp or the drugs action will be prolonged)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

What changes in potassium are associated with NMBDs?

A

Acute hypokalemia
- hyperpolarize the cell
- resistance to depolarizing NMBDs
- increased sensitivity to non depolarizing NMBD
Acute hyperkalemia
- decreases Vrm (partial depolarizes cell)
- increases effects of depolarizing NMB
- resistance to non-depolarizing NMBs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

When do burn patients have increased resistance to non-depolarizing NMBs?

A

10 -60 days post injury → need more of drug to have the same effect

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Double the dose of __________ will have onset similar to succinylcholine

A

Rocuronium (1.2mg/kg)

double length of paralytic though

26
Q

What are NMBD considerations for a patient that has paresis/hemiplegia?

A
  • paralyzed arm: nAChRs are resistant to muscle relaxant compared to unaffected side
  • unaffected arm: still somewhat resistant to the muscle relaxant compared to normal patient
27
Q

What is the MOA of resistant to NMBD on affect side of a stroke compared to unaffected side?

A

Proliferation of extrajunctional nAchRs

28
Q

Which NMB is most likely to cause an allergic reaction?

A

Succs (although still uncommon)

likely more of a histamine reaction

29
Q

Which NMB is the least likely to cause an allergic reaction?

A

Cisatracurium

30
Q

What can cause cross reactivity with NMB?

A

Quaternary ammonium group→ seen with soaps and cosmetics that can cause allergic reactions with NMBDs

31
Q

Why are women more sensitive to NMBDs than males?

A

Women have less muscle mass and more fat (NMB lasts longer)
- need 22% less Vec
- need 30% less Roc

32
Q

What is the TI for pancuronium?

A

1: toxic dose is the same a effective dose

33
Q

What is the intubating dose, onset, and duration of Pancuronim?

A

0.1 mg/kg
Onset: 3-5 min
Duration: 60-90 min

34
Q

What is the main reason pancuronium isnt used?

A

Vagolytic properties (tachycardia)

35
Q

What is the metabolism of Pancuronium?

A

80% elimination unchanged in urine

36
Q

How does elimination of pancuronium change in renal failure, liver disease, and aging?

A

In renal failure
- 30-50% decreased plasma clearance
- 10-40% deasacetylpancuronium metabolite ½ as active (by liver)

In liver disease
- Increased VD
- Larger initial dose is needed
Prolonged elimination ½ time

In aging
- Decreased plasma clearance d/t renal function

37
Q

What are CV effects of Pavulon?

A

↑ HR, MAP, CO
- d/t vagal blockade
- Mostly at SA node
- BP increase d/t HR

d/t SNS activation
- Release of NE presynaptically
- Blockade of NE reuptake

No changes in SVR or inotropy

No histamine release

38
Q

How do you decide which intermediate acting NMBD if they all have the same onset and duration?

A

Look at differences in metabolism (co-morbidities of the patient)

39
Q

Onset, duration, CV effects of intermediate NMBs compared to Long acting NMBs:

A
  • Similar onset of maximum blockade
    (except high dose roc)
  • Approximately 1/3 duration of action
  • Minimal/absent cardiovascular effects
  • Antagonized by anticholinesterase drugs approx 20 min.
40
Q

What is the dose, onset, duration, and trade name for Vecuronium?

A
  • Norcuron
  • 0.1mg/kg
  • O: 3-5 min
  • D: 20-35 minutes to be reversible
41
Q

How is Vecuronium metabolized/excreted?

A
  • Hepatic metabolism: Primary organ of elimination (70%)
  • Metabolite: 3-desacetylvecuronium 50-80% as potent but rapidly converted to metabolite 1/10 as potent
  • Renal excretion: 30% unchanged, prolonged 1/2 time with renal dysfxn
42
Q

What are considerations when giving Vec to elderly pts?

A
  • Decreased Vd (less muscle mass)
  • Decreased plasma clearance (less hepatic flow)
43
Q

What are considerations with Vec and pregnant women?

A
  • insignificant effects to fetus
  • increased clearance in 3rd trimester (progesterone)
  • prolonged duration early postpartum (give IBW)
44
Q

How does acid-base imbalances affect blockade with Vecuronium?

A

Depends on when the acid-base status changed
- Prior to NMBD→ no prolonged block
- Resp Acidosis after NMBD given→ prolonged block

45
Q

How does acidosis affect MOA of Vec?

A
  • Acidosis decreases bound amount→ paralyzed longer than if pH was normal
  • change in ionization at receptor increases attachment time
46
Q

What would be a concern in post op if patient had vec during procedure?

A

Hypoventilation→ acidosis

47
Q

What are CV effects of Vec?

A

none and no histamine release 🤠

48
Q

What is the dose, onset, duration, and trade name for Rocuronium?

A
  • Zemuron
  • 0.6 mg/kg or 1.2 mg/kg (high dose parallels to succs onset but pancuronium offset)
  • O: 3-5 min, 1-2 min (high dose)
  • D: 20-35 min, 60-90 min (high dose)
49
Q

How is Rocuronium metabolized?

A
  • Excreted unchanged in bile (longer DOA in liver fx and elderly d/t decrease clearance and increase Vd)
  • 10-30% renal excretion (marginal affect in renal fx)
50
Q

What NMBDs would we want to avoid in liver pts?

A

Vecuronium
Rocuronium

51
Q

What are CV effects of Rocuronium?

A

none, no histamine release

52
Q

What is the dose, onset, duration, and trade name for Cisatracurium?

A
  • Nimbex
  • 0.1mg/kg
  • O: 3-5 min
  • D: 20-35 min
53
Q

How is Nimbex metabolized?

A

Degradation
- Hoffman elimination (temp dependent)
- Doesnt use non-specific plasma cholinesterases as much as Atracurium

54
Q

Cisatracurium is the ____ isomer

A

Cis (no histamine)

Recovery from infusion not affected by time

55
Q

What pt pops affect pharamcokinetics of Nimbex?

A
  • Elderly: delay in onset (1 min) d/t CO
  • Obese: DOA prolonged if dosed on actual body weight d/t Vd
56
Q

What are CV effects of Nimbex?

A

None, no histamine release

57
Q

Are there any short acting non-depolarizing NMBDs on the market currently?

58
Q

What is the dose, onset, duration, and trade name of mivacurium?

A
  • Mivacron
  • 0.15mg/kg
  • O: 2-3 minutes
  • D: 12-20 minutes (short)
59
Q

Why is Mivacron no longer on the market?

A

Did not provide a great paralysis “MOVE-acron🥴”

60
Q

What was Mivacron good for when it was in clinical use?

A

Super fast procedures:
- drilling pin in finger
- mediastinoscopy for node biopsy in trachea

61
Q

How it mivacurium metabolized?

A

3 stereoisomers
- Cis-cis
- Cis-trans (NM blocking ability)
- Trans-trans (NM blocking ability)

Cleared by plasma cholinesterases

62
Q

What CV effects are associated with Mivacron?

A

Minimal
Histamine release
- >3X ED95 (transient MAP drop)
- more common with rapid, large doses
- MAP drop more in HTN pts